Login to Your Account



Other News To Note


Monday, December 10, 2012

• BioCryst Pharmaceuticals Inc., of Research Triangle Park, N.C., reported that in response to recent events including the termination of its planned merger with San Francisco-based Presidio Pharmaceuticals Inc. and setbacks in their peramivir and BCX5191 programs, as well as the delay in their BCX4161 program, it is restructuring and implementing a focused strategy to advance its hereditary angioedema (HAE) and antiviral programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription